Year: 2019
Type: review
Abstract: Cancer is a dreaded word, which has stimulated monumental efforts to discover and deliver effective cancer treatments for more than half a century. During the past two decades, our understanding of the molecular pathogenesis of cancer has increased remarkably. This has fostered an explosion in the number of experimental agents and clinical trials coupled with a dramatic rise in the regulatory approval of therapies for human cancers. Unfortunately, our preclinical models perform poorly as predictive platforms for the ultimate success of clinical candidates, reflecting the complexity of cancer. Moreover the common combination of cancer drugs prescribes the need for a better understanding of the fundamental pharmacology of each agent. Here I briefly outline some of the fundamental changes that have and have not occurred in cancer pharmacology during the past two decades and prognosticate on possible future directions.
DOI: 10.1002/prp2.527
Author: John S. Lazo
Institution: University of Virginia
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,500
Awards: Small Molecule Inhibitors of Tyrosine Phosphatase PTP4A3: A Novel Therapeutic Paradigm for Treating Breast Cancer, G4119534169, G4227651088, G5850682332, G6846596202, G8166743225, Developing small molecule PTP4A3 inhibitors for ovarian cancer, University of Virginia Cancer Center Support Grant, SMALL MOLECULE INHIBITORS OF TYROSINE PHOSPHATASE PTP4A3 A NOVEL THERAPEUTIC PARADIGM FOR TREATING BREAST CANCER
OpenAlex ID: W2979343256